Anti-Human C6 Monoclonal Antibody (clone WU 6-4) -100 µg (CAT#: CB-P175-AB) Datasheet

Product Type
Antibody
Description
The monoclonal antibody WU 6-4 recognizes C6, which is one of the components of the terminal complement complex (TCC), also known as the membrane attack complex (MAC). The proteolytic cleavage of C5 by C5 convertase produces C5b, which initiates the assembly of C5b-9 MAC. The complex is assembled from five precursor molecules in the serum, and finally with the polymerization of C9, the complex is inserted into the cell membrane to cause cell lysis. Polymorphonuclear leukocytes represent the main source of C6. After incorporating TCC, the monoclonal antibody WU 6-4 recognizes natural C6, but not C6. In addition, WU 6-4 can inhibit the formation of C5b6 and TCC in the liquid phase, and inhibit hemolysis to a lesser extent. Only the introduction of WU 6-4 before the formation of C5b6 can inhibit hemolytic activity.
Disease
Infectious diseases, Nephrology
Size
100 µg
Immunogen
Human C6
Species
Human
Cross reactivity
Rabbit
Host
Mouse
Clonality
Monoclonal
Isotype
Mouse IgG1
Clone Number
WU 6-4
Buffer
PBS, containing 0.1% bovine serum albumin.
Application
Flow cytometry, Functional studies, Immuno assays, Immuno fluorescence, Immuno precipitation, Paraffin sections, Western blot
Application Notes
For immunohistology, flow cytometry, and western blotting, the diluent that will be used depends on the detection system used. It is recommended that users test reagents and determine their own optimal dilution. The typical initial working dilution is 1:50. For functional studies, the in vitro dilution must be optimized in the user's experimental setting.
Storage Instructions
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year.
Target
C6
Alternative Names
C6; complement C6

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK